1The Strait of Hormuz risk has moved from headline to shipping operations
Six separate Reuters items in the day's general-news feed pointed at one stretch of water. A vessel was fired on. The UN suspended its escort and evacuation operation for ships transiting the strait. Iraq warned it could leave OPEC. Security around the Dubai shipping hub came under scrutiny, and India's energy relationship with Iran drew fresh attention. It was the most-covered theme of the morning by some distance.
The sixth item cuts against the other five: crude shipments through the corridor are running at their highest level of the war. Cargo is still moving, in record volume, which means the escalation is currently being absorbed as a cost-and-logistics problem — escorts, insurance, routing — rather than as a supply shortfall. That distinction is what separates a premium on passage from a premium on scarcity, and only the second one takes barrels out of the market. Energy names have been responsive without being repriced wholesale; Kosmos Energy rose about 10% pre-market earlier in the week.
So the number worth watching is the flow, not the headline count. While shipments hold at war-highs, this is priced as friction. The session that number falls is the session it becomes a supply story.
2Gold fell about 20% while central-bank buying underneath it never paused
Felix, on Felix & Friends, reads the roughly 20% fall in gold as a speculator and momentum unwind rather than a change in the structural bid, and the survey evidence he cites is the strongest material on the page. A record 45% of the central banks surveyed plan to add gold — up from 43% last year and 8% in 2019 — and official-sector buying has run at roughly 1,000 tonnes a year for four consecutive years, straight through the drawdown as well as the rally.
The reason given is more interesting than the quantity. For the first time in that survey's history, geopolitical instability displaced inflation as the top reserve concern, named by 80%, and 75% of respondents expect the dollar's share of global reserves to fall. That is a change in what reserve managers think reserves are for — insurance against a political event rather than against a price level. It also connects straight back to the first section: the buying is a response to precisely the kind of event unfolding in Hormuz.
Two things to hold against it. This is one channel's argument, and nothing else in the day's material corroborates either the framing or the survey. And the video is built around a promotional funnel — a free report, a weekend webinar, a teaser about one supposedly dangerous date in August — so the structural numbers are worth considerably more than the packaging around them.
The consequence, if the framing holds, is that a price set by two bid pools of very different speed can fall a fifth without the slower pool changing its behaviour at all.
3Rate-hike odds are rising into a budget where interest already costs more than defence
A Motley Fool piece carried on Yahoo Finance describes the probability of a Fed rate hike as "soaring" and calls it a "serious problem for Wall Street". The tape agreed at the margin: the VIX rose 4.3%, to about 19.7, going into the session.
Felix's macro argument is the direct contradiction of that, and it is worth stating in full because it is falsifiable. His case is that the Fed cannot hike. Federal interest expense now exceeds defence spending, so a higher policy rate compounds the fiscal problem it is meant to solve, and an attempt would meet a bond-market reaction like the one that ended the UK's 2022 mini-budget. On that reading, negative real rates are the default policy outcome rather than a choice — which is the mechanism sitting underneath the gold argument above.
One source says hike risk is rising; the other says a hike is structurally unavailable. They cannot both be right, and the test is cheap, because the next meeting either moves or it does not. What neither of them addresses is the middle case: that the Fed hikes and the bond market absorbs it, which would leave the equity warning and the gold thesis without their respective supports at the same time.
4The memory shortage has stopped being a chip story and reached the price tags
Apple is raising MacBook and iPad prices because of the memory crunch, per Finnhub's coverage, which framed the company as able to weather the storm. fell 6.15% on the day, per Yahoo Finance. That is a pass-through completing: a component shortage previously visible only in supplier revenue is now in the shelf price of a finished device, and at the device maker the first-order question that raises is demand, not margin.
The supplier side of the same shortage is being marked both ways at once. Yahoo Finance wrote up Micron approaching the trillion-dollar club on memory strength; the same morning, Google News had memory names down about 4% pre-market — and SanDisk — with AI and CPU chips off about 3%, and among them. Qualcomm was the exception, jumping on a ByteDance deal, and Oracle was upgraded to buy.
So the same shortage is a revenue line for whoever makes the memory and a cost line for whoever buys it, and on this particular morning both sides were sold. A cost pass-through that reaches the consumer is also an inflation input, which is where this meets the rate argument above.
What the sources recommended
One named buy came out of the day's two videos, and three separate warnings travel with it.
The buy is (Vera Therapeutics), from Ross Givens, on a dated catalyst: an FDA accelerated-approval decision on 7 July for atacicept, in IgA nephropathy. The science is substantially de-risked — the ORIGIN Phase 3 trial hit, with a 46% reduction in urine protein and a 42% improvement over placebo, and the filing carries priority review. Eight analysts rate it strong buy against an average target near $83.50 (low $56, high $110) versus roughly $35 spot, and the stock has already run 23–24% in a fortnight, back above both its 50- and 200-day moving averages.
The caveats belong with the call. Givens frames it explicitly as an event trade to be sized small — his words are not to go 200% long — and not a position to carry into the 2027 full-approval data; accelerated approval can still be delayed, sent back for more data, or refused outright. He also names the wrong ticker on air, calling it "V", which is Visa's symbol rather than Vera's. And the video runs a paid-service promotion alongside prior-win bragging — a 150%-in-12-days claim, a "batting a thousand" line — so the dated FDA decision is the part worth keeping and the framing around it is not. Outlook Therapeutics appears in the same video as an earlier win, not as a fresh call.
The gold argument in the second section never became a ticker. What was recommended there was an allocation — 5–10% of a portfolio, the traditional weighting — held in physical metal or miners generally, with the timing point being to buy ahead of institutional flow rather than into it.
With no macro release on the calendar, the session trades geopolitics
US earnings are light today — and before the open — and Finnhub's calendar window carries no major macro release, so there is nothing scheduled to displace either the Hormuz story or the rate argument. The VIX at roughly 19.7, up 4.3%, is where any of it shows up first.
The cleanest scheduled test on this page is 11 days out: 's FDA decision on 7 July is a binary that either validates the catalyst trade or ends it, with no partial credit. PepsiCo reports on 9 July and Delta on 10 July.
